Trial reportClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial.
Trial report in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 54 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled Trial
Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study
Who cites it
54 citing papers in PubMed, 9 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Pooled it
- Evidence for the Use of Patient-Reported Outcome Measures in the Treatment of Patients With Noncommunicable Diseases: Systematic Review.JMIR medical informatics · 2025Pooled it
- Psychological interventions for treatment of inflammatory bowel disease.The Cochrane database of systematic reviews · 2025Pooled it
- The effectiveness of continuity of care in patients with inflammatory bowel disease: a systematic review.BMC gastroenterology · 2024Pooled it
- Management of Inflammatory Bowel Disease Using E-health Technologies: A Systematic Review and Meta-Analysis.Journal of Crohn's & colitis · 2023Pooled it
- Remote care through telehealth for people with inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- Patient education interventions for the management of inflammatory bowel disease.The Cochrane database of systematic reviews · 2023Pooled it
- Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores.Journal of medical Internet research · 2022Pooled it
- The cost-effectiveness of digital health interventions: A systematic review of the literature.Frontiers in public health · 2022Pooled it
- Telemonitoring of Active Inflammatory Bowel Disease Using the App TECCU: Short-Term Results of a Multicenter Trial of GETECCU.Journal of medical Internet research · 2024Trial
- Identifying and Comparing Intervention Cost Components in Remote Patient Monitoring: A Scoping Review.PharmacoEconomics · 2026Article
- Towards a Multi-sectoral Approach to Population Health: A Scoping Review of Cross-sectoral Evaluations of Health Interventions.Applied health economics and health policy · 2026Review
- A Pilot Study of the Real-World Impact of Digital Cognitive Behavioral Therapy for Inflammatory Bowel Disease (COMPASS-IBD) on Inflammation, Disease Activity, and Healthcare Use.Biopsychosocial science and medicine · 2026Article
- Implementation of values-based healthcare in inflammatory bowel disease-a review.Journal of Crohn's & colitis · 2026Review
- Health economic evaluations of digital health technologies-a rapid review of applied methods.Frontiers in digital health · 2026Review
- Lack of disparities in postoperative care after ileocecal resection in patients with Crohn's disease at tertiary inflammatory bowel diseases centers.Therapeutic advances in gastroenterology · 2026Article
- The Impact of Proactive Fecal Calprotectin Collection in an Outreach Protocol for Biologic-Naïve Ulcerative Colitis Patients-Ulcerative Colitis Clinical Outreach (UCCO).Diseases (Basel, Switzerland) · 2025Article
- Future of inflammatory bowel disease treatment: A review of novel treatments beyond guidelines.World journal of methodology · 2025Review
- Active remote monitoring of long-term conditions with mobile devices: a systematic review of cost-effectiveness analyses.NPJ digital medicine · 2025Article
- Mobile health technologies in inflammatory bowel disease: a narrative review.BMC gastroenterology · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND &
aimsTelemedicine can be used to monitor determinants and outcomes of patients with chronic diseases, possibly increasing the quality and value of care. Telemedicine was found to reduce outpatient visits and hospital admissions for patients with inflammatory bowel diseases (IBD). We performed a full economic evaluation of telemedicine interventions in patients with IBD, comparing the cost-utility of telemedicine vs standard care.
methodsWe performed a randomized trial of 909 patients with IBD at 2 academic and 2 non-academic hospitals in The Netherlands. Patients were randomly assigned to groups that received telemedicine (myIBDcoach; n = 465) or standard outpatient care (n = 444) and followed for 12 months. Costs were measured from a societal perspective. Direct healthcare costs were based on actual resource use. Indirect costs comprised self-reported hours sick leave from work, intervention costs (annual license fee of €40 per patient [$45]), and utility costs (assessed using EQ5D). Cost-utility and uncertainty were estimated using the non-parametric bootstrapping method.
resultsTelemedicine resulted in lower mean annual costs of €547/patient [$612] (95% CI, €1029-2143 [$1150-2393]; mean costs of €9481 [$10,587] for standard care and €8924 [$9965] for telemedicine) without changing quality adjusted life years. At the Dutch threshold of €80,000 [$89,335] per quality adjusted life year, the intervention had increased incremental cost-effectiveness over standard care in 83% of replications and an incremental net monetary benefit of €707/patient [$790] (95% CI, €1241-2544 [$1386-2841]).
conclusionsTelemedicine with myIBDcoach is cost saving and has a high probability of being cost effective for patients with IBD. This self-management tool enables continuous registration of quality indicators and (patient-reported) outcomes and might help reorganize IBD care toward value-based healthcare. ClinicalTrials.gov no: NCT02173002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.